Natera (NTRA) announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces publication of Signatera validation study
- Humana initiated, Paycom upgraded: Wall Street’s top analyst calls
- Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency Concerns
- Natera initiated with an Equal Weight at Wells Fargo
- Natera price target raised to $268 from $255 at RBC Capital